|[May 19, 2014]
Research and Markets: Kyowa Hakko Kirin's Nouriast for Parkinson's Disease - Forecast and Market Analysis to 2022
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/xd3gfg/nouriast)
has announced the addition of the "Nouriast
(Parkinson's Disease) - Forecast and Market Analysis to 2022"
report to their offering.
Istradefylline is a first-in-class adenosine A2 receptor inhibitor,
marketed in Japan under the brand name Nouriast by Kyowa Hakko Kirin. It
was approved in Japan for adjunct use with levodopa in advanced-stage
patients with wearing-off in March 2013, and launched in May 2013 (Kyowa
Hakko Kirin, press release, March 25, 2013; Kyowa Hakko Kirin, press
release, May 29, 2013).
Overview of Parkinson's disease, including epidemiology, etiology,
symptoms, diagnosis, pathology and treatment guidelines as well as an
overview on the competitive landscape.
Detailed information on Nouriast including product description, safety
and efficacy profiles as well as a SWOT analysis.
Sales forecast for Nouriast for the top seven countries from 2012 to
Sales information covered for the US, France, Germany, Italy, Spain,
the UK and Japan.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Nouriast (istradefylline)
For more information visit http://www.researchandmarkets.com/research/xd3gfg/nouriast
[ Back To TMCnet.com's Homepage ]